Evermore Global Advisors LLC Purchases 130,287 Shares of Enzo Biochem, Inc. (NYSE:ENZ)

Evermore Global Advisors LLC lifted its stake in shares of Enzo Biochem, Inc. (NYSE:ENZ) by 3.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,685,520 shares of the medical research company’s stock after acquiring an additional 130,287 shares during the quarter. Enzo Biochem accounts for 14.6% of Evermore Global Advisors LLC’s portfolio, making the stock its 2nd largest holding. Evermore Global Advisors LLC owned 7.92% of Enzo Biochem worth $38,587,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ENZ. JPMorgan Chase & Co. bought a new stake in shares of Enzo Biochem during the 1st quarter worth $220,000. American International Group Inc. boosted its stake in shares of Enzo Biochem by 7.1% during the 1st quarter. American International Group Inc. now owns 24,432 shares of the medical research company’s stock worth $204,000 after acquiring an additional 1,610 shares in the last quarter. Teachers Advisors LLC boosted its stake in shares of Enzo Biochem by 25.6% during the 1st quarter. Teachers Advisors LLC now owns 140,745 shares of the medical research company’s stock worth $1,178,000 after acquiring an additional 28,722 shares in the last quarter. TIAA CREF Investment Management LLC boosted its stake in shares of Enzo Biochem by 17.9% during the 1st quarter. TIAA CREF Investment Management LLC now owns 371,069 shares of the medical research company’s stock worth $3,106,000 after acquiring an additional 56,301 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in shares of Enzo Biochem by 9.2% during the 1st quarter. Vanguard Group Inc. now owns 1,665,758 shares of the medical research company’s stock worth $13,943,000 after acquiring an additional 139,901 shares in the last quarter. 63.69% of the stock is owned by institutional investors and hedge funds.

Shares of Enzo Biochem, Inc. (NYSE:ENZ) opened at $9.51 on Friday. Enzo Biochem, Inc. has a 12-month low of $6.27 and a 12-month high of $12.04.

In other news, CFO Barry W. Weiner sold 54,126 shares of the firm’s stock in a transaction on Wednesday, October 25th. The stock was sold at an average price of $10.11, for a total value of $547,213.86. Following the completion of the sale, the chief financial officer now owns 1,423,367 shares of the company’s stock, valued at $14,390,240.37. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Elazar Rabbani sold 72,401 shares of the stock in a transaction on Wednesday, October 25th. The stock was sold at an average price of $10.09, for a total value of $730,526.09. Following the sale, the chief executive officer now owns 2,038,474 shares of the company’s stock, valued at $20,568,202.66. The disclosure for this sale can be found here. In the last ninety days, insiders sold 191,398 shares of company stock valued at $1,925,292. 8.90% of the stock is currently owned by insiders.

Several equities research analysts have recently weighed in on ENZ shares. BidaskClub lowered Enzo Biochem from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. Zacks Investment Research lowered Enzo Biochem from a “buy” rating to a “hold” rating in a research note on Tuesday, August 15th. Finally, TheStreet cut Enzo Biochem from a “b” rating to a “c+” rating in a research report on Wednesday, September 27th.

ILLEGAL ACTIVITY WARNING: This story was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another website, it was copied illegally and reposted in violation of U.S. and international copyright law. The original version of this story can be read at https://www.dispatchtribunal.com/2017/12/08/evermore-global-advisors-llc-acquires-130287-shares-of-enzo-biochem-inc-enz.html.

About Enzo Biochem

Enzo Biochem, Inc is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company’s segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies.

Institutional Ownership by Quarter for Enzo Biochem (NYSE:ENZ)

Receive News & Ratings for Enzo Biochem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply